---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125337"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:50.090102+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca Q3 2024 net loss $31.2M; cash $463.3M; positive Phase 1b naporafenib data

## Summary
- Net loss of $31.2M ($0.11/share) vs $30.4M ($0.20/share) in Q3 2023.
- Cash, equivalents, and marketable securities $463.3M; expected to fund operations into H1 2027.
- R&D expenses $27.6M (up from $25.2M YoY) driven by clinical and preclinical activities.
- Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib + trametinib in NRASm melanoma bolsters Phase 3 SEACRAFT-2 conviction.
- IND filings on track: ERAS-4001 pan-KRAS inhibitor Q1 2025, ERAS-0015 pan-RAS glue H1 2025.

## SEC filing metadata
- accession: 0000950170-24-125337
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/0000950170-24-125337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/eras-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125337
- JSON: https://secwatch.observer/filing/0000950170-24-125337.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.